Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody.
We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.
Gono
Takahisa
T
The Third Department of Medicine, Shinshu University School of Medicine, Matsumoto, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
Matsuda
Masayuki
M
Shimojima
Yasuhiro
Y
Ishii
Wataru
W
Yamamoto
Kanji
K
Morita
Hiroshi
H
Hashimoto
Takao
T
Susuki
Keiichiro
K
Yuki
Nobuhiro
N
Ikeda
Shu-ichi
S
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005915:Globosides / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000627:therapeutic use*; D008297:Male; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000503:physiopathology; D011930:Reaction Time / Q000187:drug effects / Q000528:radiation effects; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D005915:Globosides; D007075:Immunoglobulin M; C051917:sulfate-3-glucuronyl paragloboside; D000069283:Rituximab